H.C. Wainwright lowered the firm’s price target on Dyne Therapeutics (DYN) to $38 from $46 and keeps a Buy rating on the shares. The reevaluated the company’s spending going forward given its competitive landscape and the pipeline development.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics: Strategic Advancements and Strong Financials Support Buy Rating
- Dyne Therapeutics reports Q1 EPS (81c), consensus (84c)
- Dyne Therapeutics expects cash to fund operations at least into 2H of 2026
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- Biotech Alert: Searches spiking for these stocks today